Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

ProBioGen-Pionyr partnership hits round two
October 2018
SHARING OPTIONS:

BERLIN & SAN FRANCISCO—A second service and license agreement is underway between ProBioGen AG and Pionyr Immunotherapeutics for the development of novel antibody therapeutics. ProBioGen will run process development and GMP manufacturing, using its CHO.RiGHT expression platform, on a second antibody from Pionyr's portfolio. No financial details were released.
 
“We developed a strong collaboration with Pionyr Immunotherapeutics on their initial antibody candidate, and we are enthusiastic about advancing a second antibody candidate into development. We consider Pionyr’s Myeloid Tuning approach to be ideally suited to target solid tumors and look forward to contributing to multiple programs with our CHO.RiGHT development and manufacturing platform. We have established a seamless team working across the two companies and are very pleased to expand our collaboration,” said Dr. René Brecht, ProBioGen's VP Process Science and Manufacturing.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.